Normal human tissues widely synthesize tissue factor (TF), also known as coagulation factor III, on their surface. Coagulation factor VII (fVII) is a serine protease precursor, primarily produced by hepatocytes in the liver and secreted into the bloodstream. Upon injury, fVII in the blood can bind its cellular receptor, TF, converting to its active form, fVIIa. This TF-fVIIa complex initiates a downstream extrinsic coagulation cascade. Cancer cells are known to overexpress TF. Formation of a protein complex between cell surface TF and plasma fVII can trigger aberrant cellular signaling via multiple pathways, resulting in malignant phenotypes. In addition, the TF-fVIIa complex may underlie a common complication associated with particular cancer types, venous thromboembolism, suggesting that TF-fVIIa signaling may be an attractive therapeutic target. Basal transcription of TF (F3) and fVII (FVII) genes in normal and cancer cells is regulated by the ubiquitous transcription factor, Sp1, and other tissue-specific transcription factors. Furthermore, the F3 gene may be activated in cancer cells in response to various stimuli associated with the tumor microenvironment. Intriguingly, FVII can be constitutively activated in non-hepatocytic cancer cells. Hypoxia, characteristic of the tumor microenvironment, can enhance expression of both F3 and FVII genes, but via distinct molecular mechanisms. In this short review, we will discuss strategies to suppress this aberrant transcription based on our current knowledge of the molecular mechanisms regulating gene expression. We will further discuss how these strategies are beneficial compared with those targeting the cell surface TF-fVIIa complex.
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Tissue factor (TF) is an integral and cell surface glycoprotein, widely expressed in normal tissues [1] . It is the cellular receptor for a zymogen, coagulation factor VII (fVII) [1] . Upon formation of the TF-fVII complex, fVII is processed to its active form (fVIIa), and triggers the coagulation cascade. fVII may present in tumor tissue fluid without tissue injury because of its presence in lymph [2] . However, levels of extravascular fVII are likely increased within tumor microenvironments, since plasma fVII may bleed through leaky blood vessels caused by proangiogenic factors, such as vascular endothelial growth factor (VEGF) produced in tumor tissues [3] . Accordingly, TF-fVIIa may be enriched in tumor tissues. TF-fVIIa signaling has been shown to facilitate many aspects of cancer progression, including cell proliferation [4] , motility [5, 6] , invasiveness [6, 7] , angiogenesis [8] and anti-apoptosis [9, 10] , via activation of the coagulation cascade and/or protease-activated receptors. Therefore this signaling pathway represents a potential therapeutic target. However, targeting TF-fVIIa signaling
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should be carefully controlled, since blocking this pathway is expected to impair normal hemostatic processes [4] .
Therapeutic approaches targeting cell surface TF-fVIIa using TF-specific antibody-based drugs have been proposed [11] . An alternative strategy to inhibit TF-fVIIa signaling in cancer cells is to target aberrant transcriptional activation of the F3 gene. The ubiquitously expressed transcription factor, Sp1, predominantly upregulates basal transcription of F3 ( Figure 1A ). Induction of F3 in cancer cells in response to various inflammatory stimuli may also be mediated by proinflammatory transcription factors, NFB, AP-1, Egr-1 and NFAT [12] . Thus, unlike Sp1, these transcription factors are potential targets. The small molecule inhibitor curcumin, a natural pigment component of turmeric spice, has been shown to block F3 induction via inhibition of NFB, AP-1 and Egr-1. Recently, it was shown that a high molecular weight chondroitin sulfate, holothurian glycosaminoglycan (hGAG), also inhibits induction of F3 by inhibiting NFB activity in melanoma cells [13] . Recently, inhibition of NFAT to block F3 expression in cancer cells has also been proposed [14] .
Cancer cells are often exposed to stress conditions such as hypoxia and nutrient insufficiency because of aberrant vasculature within tumor tissues [15] . Cancer cells can adapt to such conditions by activating various molecular mechanisms. Hypoxia is a well-known characteristic of solid tumors. In response to hypoxic stress, cancer cells upregulate transcription factors, hypoxia inducible factor-1 (HIF1) and -2 (HIF2) which subsequently activate downstream target genes [15] . Although F3 is known to be activated in response to hypoxia, numerous studies have shown that induction of F3 under hypoxic conditions is independent of these HIFs in normal [16] and cancer cells [17] . Instead, induction of the Egr-1 transcription factor under hypoxic conditions plays a major role in F3 induction [16, 17] . Egr-1 may replace Sp1 binding ( Figure 1B ), as these transcription factors share the same GC-rich cis-acting elements within gene promoters [12] . Egr-1 may also bind unoccupied cis-acting elements similar to Sp1 consensus motifs within the F3 promoter region [12] . Taken together, unlike roles in basal expression, Sp1 does not contribute to hypoxia-driven F3 induction. Previous studies have shown that Egr-1 may be targeted by curcumin, similarly to NFB and AP-1, leading to inhibition of hypoxic F3 expression [18] .
Transcriptional activation of FVII has not been considered a target of aberrant TF-fVIIa signaling, since fVII is thought to originate from the bloodstream. However, studies have shown that multiple cancer cell types can ectopically synthesize fVII [19] . Notably, several breast cancer cell lines highly express fVII at both the mRNA and protein levels, and exhibit procoagulant activity on their cell surface [19] . These data indicate that cancer cells may autonomously produce the TF-fVIIa complex, and that in addition to TF, ectopically expressed fVII may be a potential therapeutic target.
Mechanisms regulating FVII gene transcription in human hepatocytes have been extensively characterized [20] [21] [22] . These studies revealed that HNF-4, which exhibits tissue-selective expression, and Sp1 bind to the FVII promoter and cooperate to activate expression ( Figure 2A ). Thus, Sp1 is a critical positive regulator of basal FVII transcription, as for the F3 gene. However, it is likely that proinflammatory transcription factors responsible for upregulating F3 are not involved in FVII regulation [11] . Previously, we found that Egr-1, USF-1 and CREB transcription factors are recruited to the active FVII promoter in hepatocytes [23] (Figure 2A ). Egr-1 and USF-1 negatively regulate hepatocytic FVII expression, while CREB upregulates expression [23] (Figure 2A ). Thus, steady-state levels of FVII transcript in hepatocytes are controlled by interplay among multiple transcription factors.
In breast cancer cells, Sp1 binding to the same cis-element is crucial for ectopic expression of FVII, while HNF-4 is dispensable [23] ( Figure 2B ). Furthermore, expression of FVII is high in breast cancer cells irrespective of the presence of estrogen and progesterone receptors [19, 23] . Egr-1, USF-1 and CREB are also involved in ectopic expression of FVII, as seen in hepatocytes [23] ( Figure 2B ). These transcription factors, in particular Sp1, are strongly bound to the active FVII promoter in breast cancer cells. However, expression of these transcription factors was similar among tested cancer cell lines, regardless of the variation in FVII expression levels [23] . These results suggest that enhanced binding of these factors is responsible for high FVII expression. The ectopic FVII expression is not regulated by the transcription factor c-Myc [23] , although this transcription factor may associate with target DNA sequences similar to that of USF-1. The transcription factors described above are poorly bound to the inactive FVII gene promoter in cancer cells with low FVII expression ( Figure 2C ). Taken together, these studies indicate that ectopic FVII expression is more dependent on Sp1 in breast cancer cells compared with its hepatocytic expression.
Sp1 is a well-characterized transcription factor involved in the basal regulation of numerous house-keeping genes [24] , and is vital for normal cell function. The function of Sp1 can be controlled by a number of post-translational modifications, including phosphorylation, acetylation and SUMOylation and protein-protein interactions [24] . However, increasing evidence suggests that Sp1 also plays a role in inducible gene expression [24] . Notably, Sp1 has been shown to control gene expression specifically associated with cancer progression [24] . We found that Sp1 also contributes to FVII gene induction under hypoxia in multiple cancer cells [25] . Intriguingly, mechanisms of hypoxic FVII induction differ significantly from that of F3 described above. We found that Egr-1 associates with the FVII promoter chromatin [25] . However, promoter occupancy was not enhanced in response to hypoxia in ovarian cancer cells, although Egr-1 protein levels were increased [26] . This mechanism also differs from conventional transcriptional induction by HIFs, which form heterodimeric complexes with the arylhydrocarbon receptor nuclear translocator (ARNT), and subsequently bind target DNA sequences referred to as hypoxia responsive elements (HREs) ( Figure 3A) . In addition to controlling basal expression of F3 and FVII, activation of FVII under hypoxic conditions is mediated by Sp1, although Sp1 binding to the FVII promoter is not enhanced under hypoxia [25] . As in the case of common hypoxia inducible genes, such as VEGF, GLUT1 and ENO1, HIFs are major transcription factors regulating hypoxia-induced FVII expression [25] . However, unlike HRE-dependent mechanisms, binding of HIF2 is mediated via Sp1-association with the FVII promoter region [25] (Figure 3B ), suggesting that HIF2 acts as a transcription factor coactivator. HIF1 is also involved in the activation of FVII, but this is independent of ARNT [25] . Cooperation of HIFs with USF-1 and CREB for transcriptional activation has not been examined, although recent studies demonstrate that HIFs may collaborate with USF-1 [27] and CREB [28] to regulate hypoxic gene expression. In summary, transcription of F3 may be constitutively and inducibly upregulated in cancer cells by Sp1 and multiple transcription factors that are activated in response to various extracellular stimuli. FVII can be constitutively activated by Sp1 in breast cancer cells. Unlike the promoter region of the F3 gene, the FVII promoter may not respond to proinflammatory transcription factors, resulting in the inability to adapt to a hypoxic tumor microenvironment via the above stress-responsive transcription factors. Thus, it is conceivable that Sp1, instead of proinflammatory transcription factors, mediates both constitutive and ectopic FVII gene activation in cancer cells.
Coactivators indirectly bind DNA sequences via interactions with transcription factors, and are crucial mediators of gene expression. A major class of coactivators are histone acetyltransferases (HATs). Identification of HATs associated with the FVII promoter may lead to the development of novel strategies to block ectopic FVII expression in breast cancer cells. Thus, HATs associated with hepatocyticand ectopic FVII promoter chromatin were explored. Various HATs (p300, CBP, PCAF, and SRC-1) can be recruited to hepatocytic FVII promoter chromatin, although the specific HATs vary depending on cell and tissue types [23] (Figure 2A and B) . However, in breast cancer cells, p300 and CBP predominantly associate with active FVII promoter chromatin; this is also true in clinical breast cancer samples [23] ( Figure 2B ). Indeed, levels of histone H4 acetylation at active FVII promoter chromatin are higher than at relatively inactive FVII promoters [23] . These results are consistent with conventional transcriptional activation mechanisms, where active gene promoter regions are associated with hyperacetylation of histones [25] .
The acetylation status of histones within the FVII promoter region in ovarian cancer cells, relative to hypoxia-driven activation, was analyzed. The level of acetylation was relatively low in these cells, corresponding to the low basal expression of FVII [25] . However, unexpectedly, the level of histone acetylation was further decreased in response to hypoxia [25] , suggesting that FVII induction is associated with histone deacetylation. This suggests that histone deacetylases (HDACs) may act as coactivators in the context of hypoxic FVII induction. Generally, recruitment of HDACs to gene regulatory regions is associated with the formation of inactive chromatin, with deacetylation of histones [29] . HDACs may also contribute to gene regulation by deacetylating various proteins involved in gene regulatory mechanisms [29] . Investigation of HDACs associated with FVII promoter chromatin in ovarian cancer cells revealed that HDAC4 (a class II HDAC) is recruited to the FVII promoter chromatin in response to hypoxia [25] ( Figure 3B ). This association of HDAC4 with the FVII promoter is potentially mediated by interaction with HIF2 [25] . In contrast to the indirect binding of p300 to HRE present in the VEGF gene enhancer region ( Figure 3A) , association of p300 with the FVII promoter is not increased under hypoxic conditions [25] . We also detected class I and III HDACs at the FVII promoter; however, binding was not enhanced in response to hypoxia, suggesting that HDAC4 is indeed responsible for FVII activation [25] . Intriguingly, the mechanism of hypoxia-induced FVII induction in ovarian cancer cells is similar to that of a group of genes involved in diauxic shift occurring in yeast cells, as gene activation is accompanied by histone deacetylation within the promoters of these genes [30] .
The recruitment of specific transcription factors and their coactivators to gene promoter regions can be targeted to suppress aberrant TF-fVIIa signaling. As described earlier in this review, curcumin and hGAG can inhibit aberrant F3 expression by inhibiting Ap-1 and/or NFB transcription factors. Curcumin also blocks hypoxic F3 induction by inhibiting Egr-1 [17] ( Figure 1B) . However, the strategies employed to inhibit F3 gene induction are not applicable in the case of ectopic FVII expression, and alternative strategies are required. Previously, we demonstrated that curcumin can block constitutive FVII transcription in breast cancer cells by inhibiting p300/CBP binding to the FVII promoter [23] ( Figure 2B ). This inhibition is selective to ectopic FVII expression, which appears more dependent on p300/CBP compared with expression in hepatocytes. Anacardic acid (ACA) is a natural small molecule HAT inhibitor. However, inhibition by this compound is not selective for aberrant FVII expression, since ACA may target multiple HATs in addition to p300/CBP [23] (Figure 2A and B) . Ectopic FVII expression is also more dependent on Sp1 compared with hepatocyticexpression, therefore selective inhibition of aberrant FVII expression in breast cancer cells may be possible using small molecule inhibitor mithramycins [31] that may interfere with Sp1-DNA binding. Nevertheless, the strategies described here need to be carefully applied, as inhibition of p300/CBP and Sp1 is expected to impair normal cell functions, including hemostatic processes. Curcumin may block F3 activation by inhibiting HATs, as this compound may inhibit p300/CBP [23] . However, to date, HATs responsible for basal and inducible F3 gene activation have not been specified. Thus, selective inhibition of aberrant F3 expression by HAT inhibitors (HATi) remains obscure.
Unlike HRE-dependent expression of VEGF ( Figure 3A ), HATi such as curcumin and ACA may not be used to inhibit hypoxia-driven FVII activation, since transcriptional activation is associated with histone deacetylation ( Figure  3B ). It is conceivable, however, that HDAC inhibitors (HDACi) may suppress this aberrant FVII activation. However, concerns that HDACi-mediated inhibition may also augment basal (histone-acetylation dependent) FVII transcription exist. This possibility was tested using trichostatin-A (TSA), an inhibitor of class I and II HDACs [32] . Indeed, we observed that basal FVII transcription in cancer cells is upregulated following treatment with TSA, suggesting that HDACi-mediated inhibition of hypoxia-driven FVII activation may be unlikely ( Figure 3B ). However, given that HDAC4 may be recruited to the FVII promoter under hypoxic conditions, it would be of interest to test whether class II-specific HDACi, such as MC1568 [33] , can inhibit hypoxia-driven FVII activation. Acriflavin (ACF), a small molecule compound, may interfere with the interaction between HIFs and ARNT, thereby inhibiting expression of hypoxia-driven genes, such as VEGF ( Figure  3A) . Therefore in principle, ACF should not diminish HRE-independent gene expression, such as FVII. Indeed, as expected, FVII induction was not inhibited by ACF treatment in response to hypoxia in ovarian cancer cells [25] ( Figure  3B ). Other HIF inhibitors targeting the synthesis of HIFs [34] are expected to suppress hypoxic FVII activation. However, these drugs are unlikely to distinguish HRE-dependent transcriptional induction, thus inhibitors specific for the induction of hypoxic FVII are currently unavailable.
A possible major benefit of strategies targeting aberrant TF-fVIIa signaling at the level of dysregulated gene expression is that impairment of normal hemostatic processes is avoided. The cytoplasmic domain of TF is associated with cellular signaling, resulting in activation of the wound healing process by inducing angiogenesis [35] . Thus, selective inhibition of aberrant TF-fVIIa signaling at the transcriptional level may also allow cells to maintain a physiological inflammatory response. Moreover, combinatorial use of this transcription-targeted strategy, together with conventional strategies targeting cell surface TF, are likely to decrease the required therapeutic dosage of each drug, reducing unwanted side effects. Developing cancer therapies targeting the transcriptional machinery has long been a challenge [36, 37] . However, recent progress in our understanding of aberrant transcription machinery associated with cancer progression, including transcription factors, transcriptional coactivators and chromatin modifiers [37, 38] , reveals that these are druggable targets. One of the disadvantages of small molecule inhibitors such as curcumin is poor water solubility, resulting in low bioavailability. Thus, it is worth testing whether curcumin agents with improved solubility and cytotoxicity [39] are more efficacious in the suppression of FVII gene expression in breast cancer cells, in vivo. In addition, it would be of interest to test other new p300/CBP selective inhibitors, such as C646 [40] , for selective inhibition of ectopic FVII expression. At present, drugs that suppress hypoxia-driven FVII activation are not known and await future investigations. In conclusion, dissection of the molecular mechanisms underlying aberrant TF-fVIIa signaling at the gene expression level may lead to the development of new therapeutic strategies targeting this signaling cascade in cancer cells.
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